Literature DB >> 18175359

Redirection of flux through the FPP branch-point in Saccharomyces cerevisiae by down-regulating squalene synthase.

Eric M Paradise1, James Kirby, Rossana Chan, Jay D Keasling.   

Abstract

Saccharomyces cerevisiae utilizes several regulatory mechanisms to maintain tight control over the intracellular level of farnesyl diphosphate (FPP), the central precursor to nearly all yeast isoprenoid products. High-level production of non-native isoprenoid products requires that FPP flux be diverted from production of sterols to the heterologous metabolic reactions. To do so, expression of the gene encoding squalene synthase (ERG9), the first committed step in sterol biosynthesis, was down-regulated by replacing its native promoter with the methionine-repressible MET3 promoter. The intracellular levels of FPP were then assayed by expressing the gene encoding amorphadiene synthase (ADS) and converting the FPP to amorphadiene. Under certain culture conditions amorphadiene production increased fivefold upon ERG9 repression. With increasing flux to amorphadiene, squalene and ergosterol production each decreased. The levels of these three metabolites were dependent not only upon the level of ERG9 repression, but also the timing of its repression relative to the induction of ADS and genes responsible for enhancing flux to FPP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175359     DOI: 10.1002/bit.21766

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  35 in total

1.  Enhanced production of β-carotene by recombinant industrial wine yeast using grape juice as substrate.

Authors:  Guo-liang Yan; Heng-yu Liang; Chang-qing Duan; Bei-zhong Han
Journal:  Curr Microbiol       Date:  2011-11-13       Impact factor: 2.188

2.  Functional characterization and differential expression studies of squalene synthase from Withania somnifera.

Authors:  Neha Gupta; Poonam Sharma; R J Santosh Kumar; Rishi K Vishwakarma; B M Khan
Journal:  Mol Biol Rep       Date:  2012-06-21       Impact factor: 2.316

Review 3.  Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development.

Authors:  Chris J Paddon; Jay D Keasling
Journal:  Nat Rev Microbiol       Date:  2014-04-01       Impact factor: 60.633

Review 4.  Metabolic engineering for the production of natural products.

Authors:  Lauren B Pickens; Yi Tang; Yit-Heng Chooi
Journal:  Annu Rev Chem Biomol Eng       Date:  2011       Impact factor: 11.059

5.  High-level recombinant production of squalene using selected Saccharomyces cerevisiae strains.

Authors:  Jong Yun Han; Sung Hwa Seo; Jae Myeong Song; Hongweon Lee; Eui-Sung Choi
Journal:  J Ind Microbiol Biotechnol       Date:  2018-02-02       Impact factor: 3.346

6.  Trichomes + roots + ROS = artemisinin: regulating artemisinin biosynthesis in Artemisia annua L.

Authors:  Khanhvan T Nguyen; Patrick R Arsenault; Pamela J Weathers
Journal:  In Vitro Cell Dev Biol Plant       Date:  2011-06       Impact factor: 2.252

7.  Cloning and characterization of squalene synthase gene from Fusarium fujikuroi (Saw.) Wr.

Authors:  Rui-Yu Zhao; Wei Xiao; Hai-Li Cheng; Ping Zhu; Ke-Di Cheng
Journal:  J Ind Microbiol Biotechnol       Date:  2010-06-29       Impact factor: 3.346

Review 8.  Dynamic metabolic engineering: New strategies for developing responsive cell factories.

Authors:  Irene M Brockman; Kristala L J Prather
Journal:  Biotechnol J       Date:  2015-04-13       Impact factor: 4.677

9.  Effects of Trichothecene Production on the Plant Defense Response and Fungal Physiology: Overexpression of the Trichoderma arundinaceum tri4 Gene in T. harzianum.

Authors:  R E Cardoza; S P McCormick; M G Malmierca; E R Olivera; N J Alexander; E Monte; S Gutiérrez
Journal:  Appl Environ Microbiol       Date:  2015-07-06       Impact factor: 4.792

10.  Perspectives on using physcomitrella patens as an alternative production platform for thapsigargin and other terpenoid drug candidates.

Authors:  Henrik Toft Simonsen; Damian Paul Drew; Christina Lunde
Journal:  Perspect Medicin Chem       Date:  2009-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.